Elsevier and IDBS announce Interoperability between IDBS E-WorkBook Suite and Reaxys®

Scientists using E-WorkBook Suite can automatically integrate experimentally validated data from Reaxys into their workflow

Frankfurt, Germany and Guildford UK, February 1, 2011 - Elsevier, the world's leading publisher of scientific content and solutions and IDBS, a global provider of innovative enterprise data management, analytics and modeling solutions, announced today that Reaxys is now interoperable with the IDBS E-WorkBook Suite. The partnership creates a new mechanism that integrates best-in-class chemistry content from journals and patents with documented proprietary scientific results.

E-WorkBook Suite offers a robust and easy-to-use data management solution that is used across R&D sectors. E-WorkBook users searching for relevant chemical data can smoothly transition into Reaxys, a workflow solution that provides extensive information on chemical compounds, related physical and pharmacological properties, and synthesis information, and then save their data and findings in their workflow. With Reaxys available via E-WorkBook, a new group of researchers can now access this extensive repository of experimentally validated data.

"There is a genuine need for automatically integrating relevant chemistry information directly into the research process," said Neil Kipling, founder and CEO of IDBS. "Our partnership with Elsevier delivers essential chemical information to scientists just in time and at the point of use."

Mark van Mierle, Managing Director of Elsevier Information Systems GmbH, added. "Our customers want seamless, interoperable environments for their researchers. Our partnership with IDBS responds to customer needs and should further improve individual workflows and company productivity."

"Bringing information together in a federated search reduces the time to make decisions on which molecule to make next," said Robert Glen, Professor of Molecular Sciences Informatics at Cambridge University. "The integration of E-WorkBook and Reaxys provides an exciting new approach to improving productivity."

The combination of E-WorkBook and Reaxys accelerates user workflows in the following ways:

• Pharmacokineticists can identify when metabolites have been mentioned in the published literature, and in turn identify a host of physical property data associated with the metabolites.
• Medicinal chemists working in drug design can rapidly compare in-house proprietary information with compounds reported in patents and journals.
• Synthetic chemists, who store their own chemistry preparation information in E-WorkBook, can compare it quickly against validated published literature and find optimal synthetic routes.

E-WorkBook-Reaxys interoperability is achieved by a customized API developed by the Reaxys team linking into the IDBS ScienceLink scientific content brokerage platform. IDBS and Elsevier will continue to work closely together to provide additional innovative content-related functions to Reaxys and E-WorkBook to significantly improve how researchers interact with the world's best data.

About IDBS

IDBS is a unique, global supplier of innovative data management and first-in-class analytics solutions which increase efficiency reduce costs and improve the productivity of healthcare R&D organizations. Multinational pharmaceutical companies, major public-private healthcare partnerships, global leaders in academic study and high tech companies employ IDBS as a strategic supplier of scientific informatics and business process improvement solutions. IDBS is clearly differentiated by its unique combination of deep domain knowledge across the entire R&D sector: from the examination of the human genome at the scientist's bench, through the clinic, to translational medicine initiatives and pay-for-performance healthcare monitoring. IDBS solutions support the protection of intellectual property (IP) and the requirements for data quality and security demanded under Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and HL7 (Health Level) standards.

Founded in 1989 and headquartered in Guildford, UK, IDBS has worldwide consulting and support presence, with offices in California, New Jersey and Massachusetts, as well as in the EU, Australia and China. IDBS is a 2010 Profit Track 100 company.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

For media enquiries, please contact:

Danielle Guinebertiere, IDBS Communications Director
Tel: +1 908 429 2933
Email: dguinebertiere@idbs.com